Pires Marafon D; P Marafon D; Marafon

List of Publications by Year
in descending order

25 papers	918 citations	471477 17 h-index	580810 25 g-index
26 all docs	26 docs citations	26 times ranked	1552 citing authors

#	Article	IF	Citations
1	Elevated circulating levels of interferon-Î³ and interferon-Î³-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2017, 76, 166-172.	0.9	222
2	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. Rheumatology, 2018, 57, 1203-1211.	1.9	105
3	Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 1167-1172.	2.0	56
4	Muscle Expression of Type I and Type <scp>II</scp> Interferons Is Increased in Juvenile Dermatomyositis and Related to Clinical and Histologic Features. Arthritis and Rheumatology, 2019, 71, 1011-1021.	5.6	55
5	Temporomandibular Joint Involvement in Association With Quality of Life, Disability, and High Disease Activity in Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2017, 69, 677-686.	3.4	52
6	Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience. Journal of Rheumatology, 2015, 42, 1523-1527.	2.0	48
7	Microbiome Analytics of the Gut Microbiota in Patients With Juvenile Idiopathic Arthritis: A Longitudinal Observational Cohort Study. Arthritis and Rheumatology, 2019, 71, 1000-1010.	5.6	44
8	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	2.1	35
9	Anakinra in a Cohort of Children with Chronic Nonbacterial Osteomyelitis. Journal of Rheumatology, 2017, 44, 1231-1238.	2.0	34
10	Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors. Arthritis and Rheumatology, 2018, 70, 606-615.	5.6	28
11	Early Treatment and IL1RN Singleâ€Nucleotide Polymorphisms Affect Response to Anakinra in SystemicÂJuvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2021, 73, 1053-1061.	5.6	27
12	Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis. Journal of Rheumatology, 2017, 44, 822-826.	2.0	24
13	Lipid profiles in a large cohort of Italian children with Down syndrome. European Journal of Medical Genetics, 2016, 59, 392-395.	1.3	20
14	ProNGF-p75NTR axis plays a proinflammatory role in inflamed joints: a novel pathogenic mechanism in chronic arthritis. RMD Open, 2017, 3, e000441.	3.8	19
15	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care and Research, 2018, 70, 1312-1319.	3.4	19
16	Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factorâ€“negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication. Journal of Rheumatology, 2018, 45, 956-961.	2.0	19
17	Prediction of inactive disease in juvenile idiopathic arthritis: a multicentre observational cohort study. Rheumatology, 2018, 57, 1752-1760.	1.9	15
18	Role of ocular cytology in vernal keratoconjunctivitis. Immunity, Inflammation and Disease, 2020, 8, 3-7.	2.7	12

#	Article	IF	Citations
19	A Metaâ€Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2016, 68, 1540-1550.	5.6	11
20	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	1.9	10
21	Assessment of disease activity using a whole-body MRI derived radiological activity index in chronic nonbacterial osteomyelitis. Pediatric Rheumatology, 2021, 19, 123.	2.1	10
22	High levels of interferon-gamma (IFNÎ³) in macrophage activation syndrome (MAS) and CXCL9 levels as a biomarker for IFNÎ³ production in MAS. Pediatric Rheumatology, 2015, 13, .	2.1	7
23	Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology, 2022, 61, 1621-1629.	1.9	5
24	Statins in children: A monocentric experience. Journal of Clinical Lipidology, 2018, 12, 1326-1327.	1.5	1
25	AB0932â€…PREDICTORS OF FLARE FOLLOWING ETANERCEPT WITHDRAWAL IN PATIENTS WITH RHEUMATOID FACTOR NEGATIVE JUVENILE IDIOPATHIC ARTHRITIS DURING 48 MONTHS OF FOLLOW-UP. , 2019, , .		0